银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02591 银诺医药-B

未开盘 09-02 16:08:07

3.525

-0.210

-5.62%

最高3.840	最低3.500	成交量988.96万
今开3.750	昨收3.735	日振幅9.10%
总市值16.11亿	流通市值14.82亿	总股本4.57亿
成交额3,562万	换手率2.35%	流通股本4.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"银诺医药-B","latestPrice":3.525,"timestamp":1788336487007,"preClose":3.735,"halted":0,"volume":9889600,"delay":0,"changeRate":-0.056224899598393566,"floatShares":420285370,"shares":457000000,"eps":-0.9221849905897114,"marketStatus":"未开盘","change":-0.21,"latestTime":"09-02 16:08:07","open":3.75,"high":3.84,"low":3.5,"amount":35617859,"amplitude":0.091031,"askPrice":3.53,"askSize":56600,"bidPrice":3.525,"bidSize":127000,"shortable":3,"etf":0,"ttmEps":-0.8599725234080928,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":0,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":3.735,"openAndCloseTimeList":[[1788312600000,1788321600000],[1788325200000,1788336000000]],"volumeRatio":1.352038,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02591","defaultTab":"news","newsList":[{"id":"1107526269","title":"银诺医药-B：郑伟鹤减持，好仓比例降至7.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107526269","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107526269?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:41","pubTimestamp":1787910098,"startTime":"0","endTime":"0","summary":"郑伟鹤于2026年8月27日以每股均价3.9967港元卖出银诺医药-B股份455.00万股，涉资约1818.50万港元。郑伟鹤此次减持前持有银诺医药-B好仓3749.11万股，占比8.92%；减持后持股量为3294.11万股，好仓比例降至7.84%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119528306","title":"银诺医药-B：Cowin Capital Investment III Limited减持，好仓比例降至4.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119528306","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119528306?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:32","pubTimestamp":1787909561,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment III Limited于2026年8月27日以每股均价3.9975港元卖出银诺医药-B股份350.00万股，涉资约1399.12万港元。Cowin Capital Investment III Limited此次减持前持有银诺医药-B好仓2415.64万股，占比5.75%；减持后持股量为2065.64万股，好仓比例降至4.91%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177222002","title":"银诺医药-B：黄荔减持，好仓比例降至7.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177222002","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177222002?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:22","pubTimestamp":1787908976,"startTime":"0","endTime":"0","summary":"黄荔于2026年8月27日以每股均价3.9967港元卖出银诺医药-B股份455.00万股，涉资约1818.50万港元。黄荔此次减持前持有银诺医药-B好仓3749.11万股，占比8.92%；减持后持股量为3294.11万股，好仓比例降至7.84%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184231860","title":"银诺医药-B：Cowin Capital Investment II LTD减持，好仓比例降至4.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184231860","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184231860?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:22","pubTimestamp":1787908972,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment II LTD于2026年8月27日以每股均价3.9975港元卖出银诺医药-B股份350.00万股，涉资约1399.12万港元。Cowin Capital Investment II LTD此次减持前持有银诺医药-B好仓2415.64万股，占比5.75%；减持后持股量为2065.64万股，好仓比例降至4.91%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174539144","title":"银诺医药-B：Cowin Capital Investment Limited减持，好仓比例降至4.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174539144","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174539144?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:22","pubTimestamp":1787908968,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment Limited于2026年8月27日以每股均价3.9975港元卖出银诺医药-B股份350.00万股，涉资约1399.12万港元。Cowin Capital Investment Limited此次减持前持有银诺医药-B好仓2415.64万股，占比5.75%；减持后持股量为2065.64万股，好仓比例降至4.91%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138273560","title":"银诺医药-B：Cowin China Growth Fund II, L.P.减持，好仓比例降至4.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138273560","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138273560?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:22","pubTimestamp":1787908956,"startTime":"0","endTime":"0","summary":"Cowin China Growth Fund II, L.P.于2026年8月27日以每股均价3.9975港元卖出银诺医药-B股份350.00万股，涉资约1399.12万港元。Cowin China Growth Fund II, L.P.此次减持前持有银诺医药-B好仓2415.64万股，占比5.75%；减持后持股量为2065.64万股，好仓比例降至4.91%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729382","title":"银诺医药的下一张牌，为什么押注新兴市场？","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729382","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729382?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:14","pubTimestamp":1787793265,"startTime":"0","endTime":"0","summary":"一个在中国已获批上市、进入医保、临床数据有差异化优势的GLP-1产品，正在借助PIC/S认证、多区域BD合作的路径，向新兴市场输出。","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6340307","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","EEMO","BK4585","BK4534","EMXC","EEM","EDC","BK4504","VWO","BK4581","02591","BK4588","NEMD","EDZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173363752","title":"银诺医药-B：KOREA INVESTMENT HOLDINGS Co., Ltd.减持，好仓比例降至7.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173363752","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173363752?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:11","pubTimestamp":1787735485,"startTime":"0","endTime":"0","summary":"KOREA INVESTMENT HOLDINGS Co., Ltd.于2026年8月25日以每股均价4.1494港元卖出银诺医药-B股份392.14万股，涉资约1627.15万港元。此笔减持前持有好仓3667.40万股，占比8.73%；减持后持股量为3275.26万股，好仓比例降至7.79%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662228768","title":"银诺医药-B(02591.HK)拟斥资5000万港元进行场内H股购回","url":"https://stock-news.laohu8.com/highlight/detail?id=2662228768","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662228768?lang=zh_cn&edition=full","pubTime":"2026-08-26 07:35","pubTimestamp":1787700921,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662768170","title":"银诺医药-B(02591.HK)拟进行场内H股购回 拟定总金额5000万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662768170","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662768170?lang=zh_cn&edition=full","pubTime":"2026-08-26 07:17","pubTimestamp":1787699822,"startTime":"0","endTime":"0","summary":"格隆汇8月26日丨银诺医药-B(02591.HK)发布公告，2026年8月26日起至公司下一届股东周年大会日期止期间，其拟根据股东于2026年6月29日举行的股东周年大会上通过的特别决议案行使其于购回授权下的权力，于联交所主板以场内交易方式购回H股，拟定总金额约为5000万港元(“拟定H股购回”)。\r\n\r\n　　公告表示，在目前情况下进行拟定H股购回，显示公司对其业务展望及前景充满信心，并将最终为公司带来裨益及为股东创造价值。董事会将动用可合法作此用途的公司内部资源资金进行拟定H股购回。董事会认为，公司现有财务资源足以支持拟定H股购回，同时维持稳健的财务状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260826/32347226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115289864","title":"银诺医药-B（02591）拟斥资约5,000万港元回购H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1115289864","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115289864?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:31","pubTimestamp":1787697075,"startTime":"0","endTime":"0","summary":"财联社上海讯，2026年8月26日，广州银诺医药集团股份有限公司 发布自愿性公告称，董事会拟自2026年8月26日起至下一届股东周年大会召开日期间，在香港联交所主板以场内交易方式实施H股回购，计划动用资金总额约5,000万港元。公司回购依据为股东于2026年6月29日股东周年大会通过的特别决议所授予的回购授权，即可回购不超过当日已发行H股数量10%的股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104451706","title":"银诺医药-B宣布拟回购H股 规模最高达5000万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104451706","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104451706?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:30","pubTimestamp":1787697009,"startTime":"0","endTime":"0","summary":"银诺医药-B宣布，计划在市场上回购其H股，回购金额上限为5000万港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162924345","title":"银诺医药-B（02591.HK）发布2026年中期业绩：收入7,821.8万元，同比增长38.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162924345","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162924345?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:12","pubTimestamp":1787652744,"startTime":"0","endTime":"0","summary":"2026年8月25日，银诺医药-B公布截至2026年6月30日止六个月未经审计的中期业绩。期内，公司实现收入7,821.8万元，同比增长38.6%。毛利5,667.2万元，同比增长12.3%，但毛利率由89.4%降至72.5%。期间其他收入及收益2,658.0万元，较上年同期的524.2万元增加2,133.8万元，主要来源于政府补助收入16,543千元以及银行利息收入8,376千元。受益于收入增长及费用结构变化，公司期内亏损11,546.0万元，较2025年同期的12,247.0万元收窄701.0万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662733414","title":"银诺医药-B(02591)发布中期业绩，归母亏损1.15亿元 同比收窄5.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662733414","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662733414?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:10","pubTimestamp":1787652655,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布截至2026年6月30日止6个月中期业绩，该集团取得收入人民币7821.8万元(单位下同)，同比增加38.57%;归属于母公司拥有人亏损1.15亿元，同比收窄5.72%;每股亏损0.25元。公告称，集团于2025年2月在中国内地及于2025年9月在中国澳门商业化推出用于治疗T2D的依苏帕格鲁肽α。继2025年12月获纳入国家医保药品目录用于治疗成人T2D(自2026年1月1日起生效)后，依苏帕格鲁肽α持续获得市场覆盖及商业动力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661408692","title":"银诺医药探索药企内化AI路径，依托高质量私有数据搭建药物研发闭环","url":"https://stock-news.laohu8.com/highlight/detail?id=2661408692","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661408692?lang=zh_cn&edition=full","pubTime":"2026-08-24 11:35","pubTimestamp":1787542507,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661933260","title":"Cowin China Growth Fund II, L.P.减持银诺医药-B(02591)86万股 每股作价约4.34港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661933260","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661933260?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:22","pubTimestamp":1787311338,"startTime":"0","endTime":"0","summary":"减持后最新持股数目约为2415.64万股，最新持股比例为5.75%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260821/20260821193049_62474.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260821/20260821193049_62474.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","EWH","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108734812","title":"银诺医药-B：Cowin Capital Investment Limited减持，好仓比例降至5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108734812","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108734812?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:12","pubTimestamp":1787303526,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment Limited于2026年8月20日以每股均价4.3373港元卖出银诺医药-B股份86.00万股，涉资约373.01万港元。Cowin Capital Investment Limited此次减持前持有银诺医药-B好仓2501.64万股，占比5.95%；减持后持股量为2415.64万股，好仓比例降至5.75%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159865828","title":"银诺医药-B：Cowin China Growth Fund II, L.P.减持，好仓比例降至5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159865828","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159865828?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:11","pubTimestamp":1787303496,"startTime":"0","endTime":"0","summary":"Cowin China Growth Fund II, L.P.于2026年8月20日以每股均价4.3373港元卖出银诺医药-B（02591）H股86.00万股，涉资约373.01万港元。Cowin China Growth Fund II, L.P.此次减持前持有银诺医药-B好仓2501.64万股，占比5.95%；减持后持股量为2415.64万股，好仓比例降至5.75%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130672410","title":"银诺医药-B：郑伟鹤减持，好仓比例降至8.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130672410","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130672410?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:11","pubTimestamp":1787303480,"startTime":"0","endTime":"0","summary":"郑伟鹤于2026年8月20日以每股均价4.3369港元卖出银诺医药-B股份112.00万股，涉资约485.73万港元。郑伟鹤此次减持前持有银诺医药-B好仓3861.11万股，占比9.19%；减持后持股量为3749.11万股，好仓比例降至8.92%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286109","title":"黄荔减持银诺医药-B(02591)112万股 每股作价约4.34港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286109","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660286109?lang=zh_cn&edition=full","pubTime":"2026-08-20 19:03","pubTimestamp":1787223793,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，8月20日，黄荔减持银诺医药-B(02591)112万股，每股作价4.3369港元，总金额约为485.73万港元。减持后最新持股数目约为3749.11万股，最新持股比例为8.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","EWH","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innogenpharm.com","stockEarnings":[{"period":"1week","weight":-0.1231},{"period":"1month","weight":-0.5028},{"period":"3month","weight":-0.6461},{"period":"6month","weight":-0.8542},{"period":"1year","weight":-0.9153},{"period":"ytd","weight":-0.885}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0023},{"period":"6month","weight":-0.0173},{"period":"1year","weight":-0.0073},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州银诺医药集团股份有限公司是一家主要从事医药产品的研发及商业化的中国投资控股公司。该公司主要从事商业化原研人源长效胰高血糖素样肽-1（GLP-1）受体激动剂。该公司致力于开发糖尿病和其他代谢性疾病的疗法。该公司的主要产品依苏帕格鲁肽α（商品名：怡诺轻）用于治疗2型糖尿病（T2D）。该公司的主要候选药物管线产品包括YN014、YN401、YN209、YN203和YN202。该公司主要在国内市场经营其业务。","exchange":"SEHK","name":"银诺医药-B","nameEN":"INNOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"银诺医药-B,02591,银诺医药-B股票,银诺医药-B股票老虎,银诺医药-B股票老虎国际,银诺医药-B行情,银诺医药-B股票行情,银诺医药-B股价,银诺医药-B股市,银诺医药-B股票价格,银诺医药-B股票交易,银诺医药-B股票购买,银诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}